Cytokinetics Announces Recipients of Third Annual Communications Fellowship Grants
February 02 2021 - 7:30AM
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the
recipients of its third annual Communications Fellowship Grant
program, intended to support increased capacity in communications,
awareness building and community engagement for nonprofit
organizations.
Five grants in the amount of $20,000 each were
awarded this year to patient advocacy organizations serving the
heart failure, hypertrophic cardiomyopathy (HCM) and amyotrophic
lateral sclerosis (ALS) communities. The grants will support
projects to increase awareness, reach underserved populations,
provide assistive technologies to those in need, foster community
connections and encourage education.
“The challenges of COVID-19 have completely
transformed the care delivery model among nonprofit organizations
and the need for increased education, awareness and connectivity is
greater than ever,” said Diane Weiser, Cytokinetics’ Senior Vice
President of Corporate Communications & Investor Relations.
“We’re pleased that the Cytokinetics Fellowship Grant can enable
the development of creative approaches to better reach patient and
caregiver communities.”
The recipients of the 2021 Cytokinetics
Communications Fellowship Grants are the following:
Partnership to Advanced Cardiovascular
Health: The Partnership to Advance Cardiovascular Health
(PACH) is a coalition of patient and provider organizations working
to advance public policies and practices that result in accelerated
innovation and improved cardiovascular health for heart patients
around the world. PACH will use the grant to create an educational
patient-centric heart failure video in partnership with its member
organizations that will be disseminated among its broad network of
advocacy organizations, patient groups, scientific associations,
policy organizations and public health groups.
WomenHeart: The National Coalition for
Women with Heart Disease: WomenHeart is a patient-centered
organization that strives to advance women’s heart health through
patient support, community education, and advocacy. WomenHeart will
use this grant to hire a Communications intern who will work to
grow the organization’s reach, amplify its social media presence,
engage with media, and support other communications and marketing
needs, ensuring that heart failure patient education materials
reach those who need it.
Camp Taylor: Camp Taylor is a
medically supervised summer camp for children living with
congenital heart defects focused on creating a positive,
educational and self-affirming experience to bring joy to children
who often face emotional and social challenges. The grant will
allow Camp Taylor to serve more children affected by heart disease
in the summer camp program and expand volunteer advocacy efforts
with healthcare professionals. Additionally, the grant will support
the creation of a new in-classroom initiative to educate teachers
and classmates of children with congenital heart defects about
heart disease to create awareness, understanding and empathy for
the student.
The ALS Association Oregon and SW
Washington Chapter: The ALS Association Oregon and SW
Washington Chapter is the central source for services and education
for people with ALS, their families, caregivers and health care
professionals in all of Oregon and the six counties of Southwest
Washington. The chapter will use the grant to launch an awareness
campaign that aims to increase ALS awareness and outreach to the
underserved population of people living with ALS in remote and
rural communities in Oregon. The campaign will build awareness and
promote patient and caregiver education through virtual town halls,
live virtual education series, and virtual caregiver bootcamps. The
grant will also be used to provide more assistive technology
services to people living with ALS to ensure access to virtual
education and awareness activities.
The ALS Association Massachusetts
Chapter: The ALS Association Massachusetts Chapter serves
patients with ALS, providing no-cost services to ALS families
including support groups, home visits, insurance counseling,
referrals to community resources, education and support. The
chapter also manages an Augmentative & Alternative
Communication and Assistive Technology (AAC/AT) Program, which
provides free communication device loans and access to technologies
to individuals with ALS. With the grant, the chapter will increase
its AAC/AT Loan Program inventory and expand the program by
increasing outreach to individuals with ALS throughout New England
in collaboration with nearby chapters of The ALS Association.
About Cytokinetics’ Communications
Fellowship Program
Cytokinetics’ Communications Fellowship Program
grants are awarded annually to patient advocacy organizations
serving patients with heart failure, HCM or ALS to provide funding
in support of communications, awareness and outreach. The goal of
the Fellowship is to assist patient advocacy organizations by
increasing resources in order to better support patient communities
and bring increased awareness to the disease in the communities
they serve. The call for proposals for the 2022 Fellowship Program
will be announced in Fall 2021.
About Cytokinetics
Cytokinetics is a late-stage biopharmaceutical
company focused on discovering, developing and commercializing
first-in-class muscle activators and next-in-class muscle
inhibitors as potential treatments for debilitating diseases in
which muscle performance is compromised and/or declining. As a
leader in muscle biology and the mechanics of muscle performance,
the company is developing small molecule drug candidates
specifically engineered to impact muscle function and
contractility. Cytokinetics is preparing for regulatory
interactions for omecamtiv mecarbil, its novel cardiac muscle
activator, following positive results from GALACTIC-HF, a large,
international Phase 3 clinical trial in patients with heart
failure. Cytokinetics is conducting METEORIC-HF, a second Phase 3
clinical trial of omecamtiv mecarbil. Cytokinetics is also
developing CK-274, a next-generation cardiac myosin inhibitor, for
the potential treatment of hypertrophic cardiomyopathies (HCM).
Cytokinetics is conducting REDWOOD-HCM, a Phase 2 clinical trial of
CK-274 in patients with obstructive HCM. Cytokinetics is also
developing reldesemtiv, a fast skeletal muscle troponin activator
for the potential treatment of ALS and other neuromuscular
indications following conduct of FORTITUDE-ALS and other Phase 2
clinical trials. The company is preparing for the potential
advancement of reldesemtiv to a Phase 3 clinical trial.
Cytokinetics continues its over 20-year history of pioneering
innovation in muscle biology and related pharmacology focused to
diseases of muscle dysfunction and conditions of muscle
weakness.
For additional information
about Cytokinetics, visit www.cytokinetics.com and follow
us on Twitter, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
This press release contains forward-looking
statements for purposes of the Private Securities Litigation Reform
Act of 1995 (the “Act”). Cytokinetics disclaims any
intent or obligation to update these forward-looking statements and
claims the protection of the Act’s Safe Harbor for forward-looking
statements. Examples of such statements include, but are not
limited to, statements relating to Cytokinetics’ and its partners’
research and development activities of Cytokinetics’ product
candidates. Such statements are based on management’s current
expectations, but actual results may differ materially due to
various risks and uncertainties, including, but not limited to the
risks related to Cytokinetics’ business outlines in Cytokinetics’
filings with the Securities and Exchange Commission.
Forward-looking statements are not guarantees of future
performance, and Cytokinetics’ actual results of operations,
financial condition and liquidity, and the development of the
industry in which it operates, may differ materially from the
forward-looking statements contained in this press release. Any
forward-looking statements that Cytokinetics makes in
this press release speak only as of the date of this press
release. Cytokinetics assumes no obligation to update its
forward-looking statements whether as a result of new information,
future events or otherwise, after the date of this press
release.
Contact:Diane WeiserSenior Vice
President, Corporate Communications, Investor Relations(415)
290-7757
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Sep 2023 to Sep 2024